Events Search and Views Navigation
April 2020
May 2020
June 2020
FierceBiotech VIRTUAL SERIES: CLINICAL TRIALS
In their hunt for new approvals, biopharma companies spend billions of dollars every year on clinical trials. In recent years, though, real-world studies as sources of practice-informing data––and even as the basis for new indications––have multiplied. but clinical trials remain the gold standard. In a post-pandemic future, will clinical trials ever look the same again? Could real-world data help fill in the gaps? In this session, we will discuss the role real-world evidence now plays in informing clinical guidelines and…
Find out more »January 2021
California Life Sciences Association
Mark Trusheim spoke at a California Life Sciences Association briefing on January 26. The briefing was well attended, and the audience included California state legislators.
Find out more »February 2021
2021 Meetings of the ASTCT and CIBMTR
Mark Trusheim presented "Models of Paying for High-Cost Cellular Therapies" at the 2021 Meetings of the ASTCT and CIBMTR.
Find out more »BioNJ Cell & Gene Therapy Market Access Program
Mark Trusheim participated as a panelist in the BioNJ Cell & Gene Therapy Market Access Program for FoCUS.
Find out more »4th Annual Gene Therapy for Rare Disorders Conference
Mark Trusheim spoke at on the panel "Collecting & Utilizing Data to Support Gene Therapy Market Access" at the 4th Annual Gene Therapy for Rare Disorders conference representing FoCUS.
Find out more »MIT Sloan 2021 Healthcare and Bioinnovations Conference
NEWDIGS Executive Director Gigi Hirsch moderated the midday keynote fireside chat at the MIT Sloan 2021 Healthcare and Bioinnovations Conference, on the topic "The Value of Downstream Innovation - Improving Patient Access to Groundbreaking Therapies".
Find out more »